Long-Term Debt (Narrative) (Details) - USD ($) $ / shares in Units, $ in Thousands				1 Months Ended		3 Months Ended
	Oct. 31, 2018	Jun. 30, 2018	May 29, 2013	Sep. 30, 2019	Jun. 30, 2018	Mar. 31, 2020	May 21, 2013
Fda Approval Qsymia Pmr And Cvot Member
Long-term debt
Contractual Obligation Term						5 years
Marketing Expense						$ 0
Fda Approval Qsymia Pmr And Cvot Member | Minimum
Long-term debt
Contractual Obligation						180,000
Fda Approval Qsymia Pmr And Cvot Member | Maximum
Long-term debt
Contractual Obligation						$ 220,000
Convertible Notes
Long-term debt
Offering amount							$ 250,000
Debt Instrument, Interest Rate, Stated Percentage							4.50%
Net proceeds from offering			$ 241,800
Conversion price per share (in dollars per share)			$ 148.58
Repurchased Convertible Notes Face Value	$ 8,600	$ 60,000			$ 60,000
Cash payment repurchased convertible notes	7,100	$ 51,000			$ 51,000
Gain (Loss) on Extinguishment of Debt	$ 1,400
Senior Secured Note Athyrium Due 2024
Long-term debt
Debt Instrument, Interest Rate, Stated Percentage		10.375%			10.375%
Senior Notes		$ 110,000			$ 110,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		330,000			330,000
Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed					99.00%
Long-term Debt, Weighted Average Interest Rate, at Point in Time		11.30%			11.30%
Senior Secured Note Athyrium Due 2024 | Athyrium Capital Management Affiliates Member | Warrants Issued
Long-term debt
Expected life (in years)					6 years
Volatility (as a percent)					62.70%
Risk-free interest rate (as a percent)					2.83%
Dividend yield (as a percent)					0.00%
Additional Senior Secured Note Athyrium Due 2024
Long-term debt
Debt Instrument, Interest Rate, Stated Percentage		10.375%			10.375%
Senior Notes		$ 10,000			$ 10,000
Debt Instrument, Term					12 months
2024 Notes
Long-term debt
Gain (Loss) on Extinguishment of Debt				$ 0
Repayments of Notes Payable				48,600
Prepayment premiums recorded as interest expense				$ 6,400